Ultrathin anticoagulant coating as well as preparation method and application thereof
Through the combination of protein assembly and glutaraldehyde cross-linked PEI, heparin is efficiently grafted on the surface of medical materials, solving the problems of unstable anticoagulation coating and insufficient grafting amount, achieving stable and efficient anticoagulation effect. It can reduce production costs in a variety of medical materials.
Patent Information
- Application Number
- CN202411005915.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
AI Technical Summary
The anticoagulation components of the existing anticoagulation coatings are unstable and the amount of graft is insufficient, resulting in heparin shedding and reduced anticoagulation activity, affecting the durability and effectiveness of medical devices.
Through protein assembly combined with glutaraldehyde cross-linking PEI, a stable active amino base layer is constructed on the surface of medical materials, and heparin is efficiently covalently grafted to form an ultra-thin anticoagulation coating, which increases the graft amount and enhances anticoagulation performance.
It realizes stable heparin grafting, significantly improves the durability and effectiveness of the anticoagulant coating, is suitable for a variety of medical materials, and has mild processing conditions and low cost, which is suitable for a wide range of applications.
Smart Images

Figure CN118949142A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical materials, and in particular to an ultra-thin anticoagulation coating and a preparation method and application thereof. Background Art
[0002] Cardiovascular disease has become the leading cause of death worldwide. Implantable medical devices (such as catheters of extracorporeal circulation devices, central venous catheters, balloon catheters, cardiovascular stents, etc.) are widely used to treat cardiovascular diseases and the organ and tissue lesions caused by them. These medical devices that come into contact with blood are in close contact with blood, body fluids or tissues, and the interfaces between the two interact. The coagulation factors in the blood generate prothrombinase complexes under the action of certain activation factors (including endogenous and exogenous). Then, prothrombin is activated into thrombin under the action of the prothrombinase complex, which further catalyzes the conversion of soluble fibrinogen in plasma into fibrin monomers. Then, under the action of coagulation factor XIIa and calcium ions, the fibrin monomers form insoluble fibrin polymers and entrain blood cells to form gel-like blood clots. Coagulation, inflammation and other problems inevitably occur, resulting in a significant increase in the incidence and mortality of thrombotic diseases, which brings huge challenges to the design and application of cardiovascular implantable devices. Therefore, it is urgent and necessary to enhance the blood compatibility of implantable materials to meet their specific needs in different application scenarios.
[0003] Designing and developing functional surfaces of implantable materials to enhance the blood compatibility of the device surface is an important means for the device to achieve anticoagulation. Commonly used anticoagulant coatings include heparin coatings, phosphorylcholine coatings, etc. These coatings have solved the thrombosis problem associated with implantable medical devices to a certain extent. Therefore, the widespread application of anticoagulant coatings in the field of medical devices is an inevitable trend. The anticoagulant effect of heparin coatings is due to the fact that most biologically inert coatings fix heparin to the device surface through covalent bonds, which is the most widely used method to reduce thrombosis in the catheter and achieve catheter anticoagulation.
[0004] For example, CN 110585492 A discloses a medical material and a method for preparing an anticoagulant coating on its surface, comprising the following steps: S1: grafting an azide compound on the surface of the medical material to provide the surface of the medical material with amino-sensitive sites; S2: grafting a polyamino compound on the surface of the medical material obtained in step S1 to provide the surface of the medical material with an extended chain containing multiple amino groups; S3: grafting heparin on the surface of the medical material obtained in step S2 to provide the surface of the medical material with an anticoagulant coating.
[0005] However, this method still has certain limitations. The surface-bound heparin is unstable and easily leached. Due to direct contact with flowing blood and long-term exposure to the shearing effect of blood, heparin falls off, resulting in reduced anticoagulant activity and poor durability and effectiveness of the coating. In addition, due to the lack of active groups on the surface of most medical materials that can be grafted with heparin and the limitation of low tolerance processing temperature, the existing grafted heparin technology has poor applicability to medical devices.
[0006] Based on the existence of highly fibrillated sequence structures that can cause amyloid accumulation in the primary structure of proteins such as bovine serum albumin (BSA) and α-lactalbumin, and the presence of a large number of α-helical structures frozen by intramolecular disulfide bonds in their secondary structures, disulfide bond reducing agents can quickly open the intramolecular disulfide bonds, unlock their α-helical structures, and induce them to spontaneously transform into a lower-energy β-sheet, thereby forming an amyloid-like assembly. In this way, proteins can be successfully adhered to the surfaces of various biomedical materials such as metals, inorganic materials, and polymers. Through simple, rapid, low-cost, and universal adhesion coating technology, active groups are given to the material surface, and polyamine substances are used to further amplify the amount of active groups on the surface, so that an interface rich in active amino groups can be obtained, which provides support for subsequent covalent grafting. Summary of the invention
[0007] In view of the problems of unstable anticoagulant components and insufficient grafting amount of anticoagulant components in anticoagulant coatings, the present invention provides a method for preparing an ultra-thin anticoagulant coating. A stable bottom layer with active amino groups can be obtained on the surface of a substrate by combining a protein assembly with glutaraldehyde-crosslinked PEI, which can stably graft anticoagulant components such as heparin and greatly increase the grafting amount. The method is universal for implantable and interventional device materials.
[0008] To achieve the above object, the technical solution adopted by the present invention is:
[0009] A method for preparing an ultra-thin anticoagulation coating comprises the following steps:
[0010] Step 1, plasma treating the medical material to obtain an activated material;
[0011] Step 2, immersing the activated material in a solution containing reduced protein, taking it out and incubating it to obtain a medical material containing a protein coating;
[0012] Step 3, immersing the medical material obtained in step 2 in glutaraldehyde solution, polyethyleneimine (PEI) solution and NaCNBH solution in sequence, taking it out and rinsing it to obtain a medical material grafted with PEI;
[0013] Step 4, immersing the medical material obtained in step 3 in a sodium chloride solution containing aldehyde heparin for incubation, adding NaCNBH for reaction, taking out the catheter, flushing it, and soaking it in a borate buffer solution, flushing and drying to obtain the ultra-thin anticoagulant coating.
[0014] In the present invention, protein coatings are obtained on the surfaces of various biomedical materials such as metals, inorganic materials, and polymers by forming amyloid-like assemblies through proteins, and PEI is grafted onto the surface of the protein coating by cross-linking amino groups with glutaraldehyde, and a primer containing active amino groups is constructed on the surface of the substrate. Abundant active groups are given to the material surface by simple and low-cost coating technology through adhesion coating and chemical amplification technology, and then Schiff base reaction is efficiently carried out with aldehyde heparin with highly reactive groups, laying a foundation for covalently grafting sufficient heparin to construct a stable and efficient anticoagulant coating.
[0015] The plasma treatment uses one or more gases including hydrogen, oxygen and nitrogen; the surface after the plasma treatment contains abundant free radicals, which facilitates the adhesion of the subsequent reduced protein;
[0016] During plasma treatment, the gas flow rate is 80-200 mL / min, the power is 150-300 W, and the treatment time is 10-30 min.
[0017] Preferably, the plasma treatment uses oxygen, with a gas flow rate of 80-120 mL / min, a power of 180-220 W, and a treatment time of 15-25 min.
[0018] The preparation of the reduced protein solution comprises the following steps: adding a disulfide bond reducing agent (TCEP) to a 1-3% (w / v) protein solution to make the molar concentration in the solution 5-50 mM, and allowing the reaction to stand for 0.5-12 hours to obtain the reduced protein solution;
[0019] The solvent of the protein solution is one or more of trifluoroethanol (TFE), ethanol, methanol, dichloromethane and water.
[0020] In step 2, the immersion time is 30-120 seconds, and the incubation is standing at 30-37° C. for 2-12 hours; the incubation is standing in an environment with a humidity of 80-98% to allow the reduced protein to fully adhere to the surface of the substrate.
[0021] The protein includes one or more of bovine serum albumin (BSA), whey protein, silk fibroin, and keratin.
[0022] The glutaraldehyde concentration in the glutaraldehyde solution is 0.1-1% (w / v); the solvent includes one or more of water, ethanol and methanol; the catheter is immersed in the glutaraldehyde solution for 10-60 minutes, and the glutaraldehyde is uniformly adsorbed on the surface of the denatured albumin to provide sites for PEI to be covalently grafted with the substrate surface.
[0023] The PEI concentration in the PEI solution is 0.3-1% (w / v); the solvent includes one or more of water, ethanol, isopropanol, etc.; the catheter is immersed in the PEI solution for 0.5-12 hours; PEI is cross-linked with the aldehyde group of glutaraldehyde and the amino group of protein, so that PEI is more stably bound to the surface of the substrate and is not easy to fall off.
[0024] The NaCNBH solution has a NaCNBH concentration of 0.5-2% (w / v); the solvent includes one or more of water, ethanol, methanol, and isopropanol; the catheter is immersed in the NaCNBH solution for 10 minutes to 3 hours. NaCNBH reduces the imine generated by the reaction of the aldehyde group of glutaraldehyde with the amino group of PEI to a more stable ammonia, thereby obtaining a stable coating rich in active amino groups on the surface of the substrate.
[0025] The sodium chloride solution containing aldehyde heparin is obtained by mixing aldehyde heparin and sodium chloride in water, wherein the concentration of aldehyde heparin is 3-5% (w / v) and the concentration of sodium chloride is 0.9-4% (w / v), so that the aldehyde heparin molecular chain is fully stretched to expose its aldehyde group, which is convenient for reacting with the amino group on the surface of the substrate.
[0026] The preparation of aldehyde heparin includes: adding sodium nitrite and glacial acetic acid to a sodium heparin solution for reaction at room temperature for 1-6 hours, adjusting the pH to 6-9, and lyophilizing after dialysis to obtain aldehyde heparin. Heparin is cleaved to introduce aldehyde groups, and the reaction between aldehyde groups and amino groups is more efficient, so that more heparin can be covalently grafted to the surface of the substrate.
[0027] The mass ratio of the heparin sodium to the sodium nitrite is 50-200:1; the mass volume ratio of the heparin sodium to the glacial acetic acid is 50-150:1 (w / v).
[0028] In step 4, the incubation is performed at 50-70° C. for 1-60 min;
[0029] The mass ratio of NaCNBH to aldehyde heparin added in step 4 is 1:40-80.
[0030] The medical material includes one or more of polytetrafluoroethylene (PTFE) guide tube, thermoplastic polyurethane (TPU) nasogastric feeding tube, nylon (PA) catheter, TPU balloon catheter, polyetheramide (PEBAX) catheter, polyvinyl chloride (PVC) nasogastric feeding tube, and nickel-titanium alloy stent. The method of the present invention can be applied to medical materials of various materials, and can achieve a large amount of stable grafting effect of heparin.
[0031] The present invention also provides an ultra-thin anticoagulant coating prepared according to the preparation method. The ultra-thin anticoagulant coating has a thickness of 50-2000 nm, and the thickness of the protein coating and the amount of heparin grafting can be adjusted by controlling the concentration of the reduced protein solution and the concentration of the PEI solution to obtain an ultra-thin anticoagulant coating, thereby not affecting the thickness of the raw material itself, especially the material of the ultra-thin catheter.
[0032] The present invention also provides use of the ultra-thin anticoagulant coating in preparing an interventional medical device, wherein the medical device has an anticoagulant function.
[0033] Compared with the prior art, the present invention has the following beneficial effects:
[0034] (1) In the present invention, protein coatings are obtained on the surfaces of various biomedical materials such as metals, inorganic materials, and polymers by forming amyloid-like assemblies through proteins, and PEI is grafted onto the surface of the protein coating by cross-linking amino groups with glutaraldehyde, thereby constructing a primer containing active amino groups on the surface of the substrate. The simple and low-cost coating technology is used to give the material surface abundant active groups, thus laying a foundation for covalently grafting sufficient heparin to construct a stable and efficient anticoagulant coating.
[0035] (2) In the present invention, a stable primer with active amino groups can be obtained on the surface of the substrate by combining protein assembly with glutaraldehyde cross-linked PEI. The preparation process of this heparin coating is simple and the processing conditions are mild (the processing temperature does not exceed 60°C). It can be easily processed on existing medical devices, is easy to operate, has low production costs, and has broad market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is a schematic diagram of the structure construction process of the anticoagulation coating preparation process in Example 1.
[0037] Figure 2 This is an optical comparison diagram of Congo red staining after the substrate surfaces of Examples 1-4 and Comparative Example 1 were coated with BSA / PEI.
[0038] Figure 3 This is an optical comparison diagram of the substrate surfaces of Examples 1-4 and Comparative Example 2 after anticoagulant coating was applied and dyed with toluidine blue.
[0039] Figure 4 The SEM morphology images of the substrate surfaces of Examples 1-3 before and after anticoagulation coating.
[0040] Figure 5 This is an optical comparison diagram of the anticoagulant performance test of the anticoagulant coatings of Examples 1, 2, 4 and Comparative Example 1.
[0041] Figure 6 It is an optical comparison diagram of the stability test of the anticoagulation coating of Examples 1, 2, 4 and Comparative Example 1. DETAILED DESCRIPTION
[0042] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. Those skilled in the art can make modifications or equivalent substitutions based on the understanding of the technical scheme of the present invention without departing from the spirit and scope of the technical scheme of the present invention, and all should be included in the protection scope of the present invention.
[0043] The raw materials used in the following specific embodiments were purchased from the market. Heparin was purchased from Beijing Bailingwei Technology Co., Ltd.; the protein used was bovine serum albumin, which was purchased from Hangzhou Fude Biotechnology Co., Ltd.
[0044] Example 1
[0045] (1) Substrate cleaning: Place the medical PTFE catheter in a plasma cleaning machine. 2 Plasma treatment, treatment conditions are: 2 flow rate 100 mL / min, bombardment power 200 W, bombardment time 1200 s;
[0046] (2) Phase transition protein coating on substrate surface: A solution with a BSA concentration of 2% was prepared. The solvent was a 95% TFE aqueous solution containing 25 mM TCEP. The solution was allowed to stand for 2 h to allow the BSA therein to be fully reduced, thereby obtaining a solution containing reduced protein.
[0047] Then, the plasma-treated activated PTFE catheter was immersed in a solution containing reduced protein for 30 seconds, taken out and incubated at 35°C in a humid environment for 12 hours, and then immersed in deionized water for three times to wash away the strong reducing agent TCEP, thereby obtaining a stable BSA coating on the substrate surface.
[0048] (3) Surface PEI grafting: The PTFE tube was placed in a 0.5% glutaraldehyde solution for 15 min, then placed in a 0.5% PEI solution for 1 h, and finally placed in a 1% NaCNBH solution for 30 min. The sample was rinsed with deionized water.
[0049] (4) Heparin oxidation: Weigh 1 g of sodium heparin and dissolve it in 250 mL of water. Add 9 mL of sodium nitrite solution (1 mg / mL) and 7 mL of glacial acetic acid solution (500 μL of glacial acetic acid dissolved in 2 mL of water) dropwise. Stir at room temperature for 5 h. Then adjust the pH of the solution to pH 9 with NaOH. Collect the solution after the reaction with a dialysis bag and dialyze it at room temperature for 2 days. Finally, collect the dialyzed solution, freeze-dry it, and store it at 4°C.
[0050] (5) Surface heparin grafting: The PTFE catheter grafted with PEI was then placed in a sodium chloride solution of aldehyde heparin and incubated at 60°C for 30 min. 16 μL of NaCNBH aqueous solution (2.5%, w / v) was added to the above solution using a pipette, and the reaction was carried out at 60°C for 3 h. The sample was rinsed with DI water and then immersed in a borate buffer solution. The sample was rinsed with deionized water and freeze-dried to obtain a catheter containing an anticoagulant coating. The schematic diagram of each layer of grafting is shown in FIG. Figure 1 shown.
[0051] Example 2
[0052] The difference between this embodiment and embodiment 1 is that the medical catheter is a TPU catheter. 2 The plasma treatment conditions are: 2 The flow rate was 100 mL / min, the bombardment power was 300 W, and the bombardment time was 600 s.
[0053] Example 3
[0054] The difference between this embodiment and embodiment 1 is that the medical catheter is a PTFE catheter;
[0055] In addition, when the substrate surface is phase-transformed with protein coating, a solution with a BSA concentration of 3% is prepared, and the solvent is a 95% TFE aqueous solution containing 1.5M TCEP, and the solution is allowed to stand for 2 hours. Then, PTFE is immersed in the above solution for 30 seconds, taken out, placed in a humid environment at 37°C for 12 hours, and then immersed in deionized water for three times to wash away the strong reducing agent TCEP.
[0056] When PEI is grafted on the surface: the above PTFE is placed in a 1% glutaraldehyde solution and soaked for 15 minutes, then placed in a 0.5% PEI solution and soaked for 1 hour, and finally the substrate is placed in a 1% NaCNBH solution and soaked for 30 minutes, and the sample is rinsed with deionized water to obtain a PTFE catheter containing an anticoagulant coating.
[0057] Example 4
[0058] The only difference between this embodiment and embodiment 1 is that the medical catheter is a PA catheter.
[0059] Comparative Example 1 (protein not reduced)
[0060] The difference between this embodiment and embodiment 1 is that the phase transition protein coating on the substrate surface is: a solution with a BSA concentration of 2% is prepared, the solvent is a 95% TFE aqueous solution, which does not contain TCEP, and the solution is allowed to stand for 2 hours. Then, PTFE is immersed in the above solution for 30 seconds, taken out, placed in a humid environment at 35°C for 12 hours, and then immersed in deionized water for washing 3 times.
[0061] Comparative Example 2 (without PEI grafting)
[0062] The difference between this embodiment and embodiment 1 is that surface PEI grafting is not performed, step (3) is not performed, and surface heparin grafting is directly performed using the BAS coating after the protein assembly, so that the amino group on the protein reacts with the aldehyde group of the aldehyde heparin to graft the heparin to the surface of the substrate.
[0063] Performance testing of samples
[0064] (1) Amination of device surface
[0065] The aminated catheters of Examples 1, 2, 3, 4 and Comparative Examples 1 and 2 were placed in a 1% (w / v) Congo red solution and incubated for 10 min, the excess dye was washed off, the catheters were dried, and photographed to record the appearance of the dyed catheters. The dyeing results are shown in Figure 2 ; A blank original catheter is placed above each figure as a control;
[0066] It can be seen that the coatings prepared in Examples 1, 2, 3, 4 and Comparative Example 1 are obviously positive after Congo red staining, and the coatings have good integrity, which indicates that these treatment methods can obtain active amino groups on the surface of the substrate. However, the coating prepared in Comparative Example 1 has unstained parts after Congo red staining, indicating that this coating method cannot obtain a stable and complete albumin coating on the surface of the substrate. This is because after the substrate is dip-coated with the coating solution, bovine serum albumin is directly deposited on the surface of the substrate through solvent volatilization, and the interaction force between the substrate and the substrate is weak. As the solvent evaporates, the coating solution on the interface of the substrate shrinks, resulting in coating defects on the substrate.
[0067] (2) Integrity of the heparin coating on the device surface
[0068] The heparinized devices of Examples 1, 2, 3, 4 and Comparative Examples 1 and 2 were placed in a 0.005% (w / v) toluidine blue solution and incubated for 10 min, the excess dye was washed off, the devices were dried, and the appearance of the stained catheters was photographed. The staining results are shown in Figure 3 .
[0069] The coatings of Examples 1, 2, 3, and 4 are obviously purple, which is a unique color development reaction of heparin, and the color development of the coating is uniform and complete; however, after staining, almost no purple staining is visible in Comparative Example 1, which may be caused by the instability of the albumin coating, and there are almost no active amino groups on the subsequent catheter surface that can be grafted with heparin; after staining, almost no purple staining is visible in Comparative Example 2, which may be due to too few amino groups available for reaction in the albumin coating, so less heparin is grafted through the Schiff base reaction.
[0070] (3) Characterization of the thickness of the heparin coating on the device surface
[0071] The catheters of Example 1-3 were frozen and fractured by liquid nitrogen to obtain cross sections. The surface and cross sections were sprayed with gold for 40 seconds. The surface and cross sections were photographed by SEM to characterize the thickness of the coating. See the photos for details. Figure 4 . Among them, (a) is the cross-sectional morphology of the uncoated PTFE tube, and it can be seen that the cross section is a uniform phase; (b) is the cross-sectional morphology of the PTFE tube of Example 1, which is an anticoagulant coating obtained on the PTFE tube based on a 2% BSA solution, and it can be seen that there is a thin coating on the outside of the tube, and the coating thickness is 600-700nm; (c) is the cross-sectional morphology of the PTFE tube of Example 3, which is an anticoagulant coating obtained on the PTFE tube based on a 3% BSA solution, and it can be seen that there is a coating on the outside of the tube wall, and the coating thickness is greater than 1300nm; (d) is the cross-sectional morphology of the uncoated TPU tube, and it can be seen that the cross section is a uniform phase; (e) is the cross-sectional morphology of the TPU tube of Example 2, and it can be seen that there is a uniform coating with a thickness of 1200nm on the outside of the tube wall. The thickness of the heparin coating in Example 1 is 600-700 nm; the thickness of the heparin coating in Example 3 is greater than about 1300 nm. Increasing the concentration of the BSA solution and the PEI solution can increase the thickness of the coating. Therefore, the thickness of the coating can be controlled by adjusting the concentration of the coating solution, thereby obtaining an ultra-thin anticoagulant on the surface of the device, thereby achieving stable and efficient anticoagulant performance of the incubation device without affecting the performance of the original device (such as affecting the inner diameter of the ultra-fine catheter, etc.).
[0072] (4) Anticoagulant properties of heparin coating on device surface
[0073] The anticoagulant performance of the device after coating was investigated by the Chandler ring test. The heparin-coated devices in Examples 1, 2, 4 and Comparative Example 2 were fixed in medical silica gel, fresh rabbit blood was added to the silica gel tube, and the test ring was rotated in a 37°C water bath. After the experiment, the sample was gently washed in PBS, and the thrombus adhesion on the device surface was photographed with a camera. The results are shown in FIG. Figure 5 .
[0074] from Figure 5 It can be seen that there is almost no thrombus on the surface of the heparinized devices in Examples 1, 2, and 4, while there is thrombus on the surface of the device in Comparative Example 2. Combined with the research results of Congo red staining and toluidine blue staining, it can be seen that grafting a sufficient amount of heparin on the device surface can significantly inhibit the formation of thrombus and give the device surface a better anticoagulant effect; when the amount of grafted heparin is insufficient, the purpose of efficient anticoagulation cannot be achieved.
[0075] (5) Stability of heparin coating on device surface
[0076] The heparin-coated devices in Examples 1, 2, and 4 were placed in a medical extracorporeal circulation tube (mainly composed of polyvinyl chloride) and circulated at 4 L / min at 37°C. The devices were taken out after 60 days and their anticoagulant properties were tested by the Chandler ring test. The thrombus adhesion on the device surface was shown in Figure 2. Figure 6 As can be seen from the figure, the heparin-coated devices prepared in Examples 1, 2, and 4 still have excellent anticoagulant properties after 60 days of extracorporeal circulation, which indicates that the heparin coating prepared on the device surface of the present invention has good stability and can meet the clinical needs of long-term implantation or multiple uses of implantable devices.
[0077] In addition, similar experimental results have proved that the anticoagulant coatings obtained by the present invention on materials of various materials have excellent anticoagulant performance and stability, and the coating is only nanometer-level thick and will not significantly affect the performance of the original device, indicating that the ultra-thin anticoagulant coating is universal for implantable devices of different substrates and shapes and has a broad market.
[0078] The embodiments described above provide a detailed description of the technical solutions of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements or similar substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing an ultra-thin anticoagulation coating, characterized in that: Includes steps: Step 1, plasma treating the medical material to obtain an activated material; Step 2, immersing the activated material in a solution containing reduced protein, taking it out and incubating it to obtain a medical material containing a protein coating; Step 3, immersing the medical material obtained in step 2 in glutaraldehyde solution, PEI solution and NaCNBH solution in sequence, taking it out and rinsing it to obtain a medical material grafted with PEI; Step 4, immersing the medical material obtained in step 3 in a sodium chloride solution containing aldehyde heparin for incubation, adding NaCNBH for reaction, taking out the catheter, flushing it, and soaking it in a borate buffer solution, flushing and drying to obtain the ultra-thin anticoagulant coating.
2. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: The plasma treatment uses one or more gases including hydrogen, oxygen and nitrogen; During plasma treatment, the gas flow rate is 80-200 mL / min, the power is 150-300 W, and the treatment time is 10-30 min.
3. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: The preparation of the reduced protein solution comprises the following steps: adding a disulfide bond reducing agent to a 1-3% protein solution to make the molar concentration in the solution 5-50 mM, and allowing the reaction to stand for 0.5-12 hours to obtain the reduced protein solution; The solvent of the protein solution is one or more of trifluoroethanol, ethanol and water.
4. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: In step 2, the immersion time is 30-120 seconds, and the incubation is 2-12 hours at 30-37°C; The protein includes one or more of bovine serum albumin, whey protein, silk fibroin and keratin.
5. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: The concentration of the glutaraldehyde solution is 0.1-1% (w / v); the solvent includes one or more of water, ethanol, and isopropanol; the catheter is immersed in the glutaraldehyde solution for 10-60 minutes; The concentration of PEI in the PEI solution is 0.3-1% (w / v); the solvent includes one or more of water, ethanol, and isopropanol; the catheter is immersed in the PEI solution for 0.5-12 hours; The NaCNBH concentration in the NaCNBH solution is 0.5-2% (w / v); the solvent includes one or more of water, ethanol, methanol, and isopropanol; and the catheter is immersed in the NaCNBH solution for 10 minutes to 3 hours.
6. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: The sodium chloride solution containing aldehyde heparin is obtained by mixing aldehyde heparin and sodium chloride in water, wherein the mass concentration of aldehyde heparin is 3-5%, and the mass concentration of sodium chloride is 0.9-4%; The preparation of aldehyde heparin comprises: adding sodium nitrite and glacial acetic acid to a sodium heparin solution, reacting at room temperature for 1-6 hours, adjusting the pH to 6-9, and lyophilizing after dialysis to obtain aldehyde heparin; The mass ratio of the heparin sodium to the sodium nitrite is 50-200:1; the mass volume ratio of the heparin sodium to the glacial acetic acid is 50-150:1 (w / v).
7. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: In step 4, the incubation is performed at 50-70° C. for 1-60 min; The mass ratio of NaCNBH to aldehyde heparin added in step 4 is 1:40-80.
8. The method for preparing the ultra-thin anticoagulation coating according to claim 1, characterized in that: The medical material includes one or more of a polytetrafluoroethylene guide tube, a thermoplastic polyurethane nasogastric feeding tube, a nylon catheter, a thermoplastic polyurethane balloon catheter, a polyetheramide catheter, a polyvinyl chloride nasogastric feeding tube, and a nickel-titanium alloy stent.
9. An ultra-thin anticoagulation coating prepared according to the preparation method according to any one of claims 1 to 8.
10. Use of the ultra-thin anticoagulation coating according to claim 9 in the preparation of invasive medical equipment, characterized in that: The medical device has an anti-coagulation function.
Citation Information
Patent Citations
Dopamine-heparin composite anticoagulant coating and preparation method thereof
CN114984332A
Preparation method of anticoagulant coating for ECCO2R
CN117959945A
Surface modification method and application thereof
CN118307827A
Novel filter composites for drug detoxification
US20100316694A1
Cited By
Heparin coating based on material surface ammoniation modification and preparation method thereof
CN121944258A
